EDGAR Filing Documents for 0001213900-21-026146

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0001213900-21-026146

Filing Date

2021-05-13

Accepted

2021-05-13 17:19:03

Documents

Period of Report

2020-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	ANNUAL REPORT	f20f2020_biondvax.htm	20-F	2060685
2	ARTICLES OF ASSOCIATION OF BIONDVAX PHARMACEUTICALS LTD	f20f2020ex1-1_biondvax.htm	EX-1.1	309306
3	DESCRIPTION OF SHARE CAPITAL	f20f2020ex2-3_biondvax.htm	EX-2.3	104591
4	REMUNERATION POLICY	f20f2020ex4-3_biondvax.htm	EX-4.3	191401
5	AMENDMENT NO. 1 DATED JANUARY 11, 2021 TO FINANCE CONTRACT DATED JUNE 19, 2017,	f20f2020ex4-16_biondvax.htm	EX-4.16	32513
6	CERTIFICATION	f20f2020ex12-1_biondvax.htm	EX-12.1	17980
7	CERTIFICATION	f20f2020ex12-2_biondvax.htm	EX-12.2	18547
8	CERTIFICATION	f20f2020ex13-1_biondvax.htm	EX-13.1	6526
9	CERTIFICATION	f20f2020ex13-2_biondvax.htm	EX-13.2	6505
10	GRAPHIC	img_001.jpg	GRAPHIC	33604
11	GRAPHIC	image_001.jpg	GRAPHIC	2616
12	GRAPHIC	ex4-3_001.jpg	GRAPHIC	13954
	Complete submission text file	0001213900-21-026146.txt		7886637

Data Files

Seq	Description	Document	Type	Size
13	XBRL INSTANCE FILE	bvxv-20201231.xml	EX-101.INS	1333605
14	XBRL SCHEMA FILE	bvxv-20201231.xsd	EX-101.SCH	111558
15	XBRL CALCULATION FILE	bvxv-20201231_cal.xml	EX-101.CAL	32726
16	XBRL DEFINITION FILE	bvxv-20201231_def.xml	EX-101.DEF	283179
17	XBRL LABEL FILE	bvxv-20201231_lab.xml	EX-101.LAB	587432
18	XBRL PRESENTATION FILE	bvxv-20201231_pre.xml	EX-101.PRE	293620

Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000

Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529

BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)